AbbVie Bid to Block Humira Rival to Be Probed at Trade Agency

The U.S. International Trade Commission has launched an investigation based on a complaint AbbVie filed seeking to block a biosimilar of its $20 billion-a-year arthritis drug Humira by Alvotech.

• AbbVie also named Teva, which has agreed to sell the Iceland-made Alvotech copy, called AVT02, in the U.S. in a deal worth more than $450 million, according to the complaint
• AbbVie said Alvotech recruited employees in Singapore to steal confidential information on the manufacturing process to create Humira, and continues efforts to poach AbbVie employees
• Alvotech, which denies any theft, told the agency that an import ban would be against ...